TIM
MRTX

Thornburg Investment Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Thornburg Investment Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-41,397
Closed -$7.09M – 233
2021
Q1 		$7.09M Buy
41,397
+4,349
+12% +$861K 0.08% 142
2020
Q4 		$8.14M Buy
+37,048
New +$8.01M 0.1% 149

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Thornburg Investment Management's MRTX Position: Q2 2021 in Review

Thornburg Investment Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2021, closing a stake of 41,397 shares — an estimated $7.09M sold.

Thornburg Investment Management first reported a position in MRTX in Q4 2020 and held it in 2 quarters. The position peaked at $8.14M in Q4 2020. 245 funds tracked by Wall St. Rank hold MRTX as of Q2 2021.

  • Thornburg Investment Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Thornburg Investment Management sold 41,397 Mirati Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $7.09M.
  • Thornburg Investment Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Thornburg Investment Management's Mirati Therapeutics, Inc. Common Stock position peaked at $8.14M in Q4 2020.
  • 245 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Thornburg Investment Management's 13F filing for Q2 2021, filed 11 Aug 2021.